NEWS Dean A. Wetherbee 6/15/22 Dean A. Wetherbee 6/15/22 Thetis Pharmaceuticals Announces Patent Issuance in China for First-in-Class Resolvin E1 Drug Read More Dean A. Wetherbee 4/5/22 Dean A. Wetherbee 4/5/22 Thetis Pharmaceuticals Secures $4.2 Million From the Helmsley Charitable Trust to Advance Its First-in-Class, Oral Resolvin E1 Therapy for Crohn’s Disease Read More Dean A. Wetherbee 12/2/21 Dean A. Wetherbee 12/2/21 Chris Takimoto, MD, PhD, Physician-Scientist and Oncology Drug Developer, Joins Thetis Pharmaceuticals Scientific Advisory Board Read More Dean A. Wetherbee 10/13/21 Dean A. Wetherbee 10/13/21 Sui Huang, MD, PhD, Pioneering Cancer Biology Researcher, Joins Thetis Pharmaceuticals Scientific Advisory Board Read More Dean A. Wetherbee 8/23/21 Dean A. Wetherbee 8/23/21 Thetis Pharmaceuticals Announces Patent Issuance in Japan for its Resolvin E1 candidate, TP-317, for Inflammatory Bowel Disease and Cancer Read More Dean A. Wetherbee 7/8/21 Dean A. Wetherbee 7/8/21 Thetis Pharmaceuticals Launches Resolvin E1 Cancer Program and Scientific Advisory Board Read More Dean A. Wetherbee 1/20/21 Dean A. Wetherbee 1/20/21 Thetis Pharmaceuticals Completes Pre-IND Meeting with FDA for its first-in-class Resolvin E1 Candidate Read More Dean A. Wetherbee 12/14/20 Dean A. Wetherbee 12/14/20 Thetis Pharmaceuticals Receives Orphan Drug Designation for Resolvin E1 Program in Pediatric Ulcerative Colitis Read More Newer Posts
Dean A. Wetherbee 6/15/22 Dean A. Wetherbee 6/15/22 Thetis Pharmaceuticals Announces Patent Issuance in China for First-in-Class Resolvin E1 Drug Read More
Dean A. Wetherbee 4/5/22 Dean A. Wetherbee 4/5/22 Thetis Pharmaceuticals Secures $4.2 Million From the Helmsley Charitable Trust to Advance Its First-in-Class, Oral Resolvin E1 Therapy for Crohn’s Disease Read More
Dean A. Wetherbee 12/2/21 Dean A. Wetherbee 12/2/21 Chris Takimoto, MD, PhD, Physician-Scientist and Oncology Drug Developer, Joins Thetis Pharmaceuticals Scientific Advisory Board Read More
Dean A. Wetherbee 10/13/21 Dean A. Wetherbee 10/13/21 Sui Huang, MD, PhD, Pioneering Cancer Biology Researcher, Joins Thetis Pharmaceuticals Scientific Advisory Board Read More
Dean A. Wetherbee 8/23/21 Dean A. Wetherbee 8/23/21 Thetis Pharmaceuticals Announces Patent Issuance in Japan for its Resolvin E1 candidate, TP-317, for Inflammatory Bowel Disease and Cancer Read More
Dean A. Wetherbee 7/8/21 Dean A. Wetherbee 7/8/21 Thetis Pharmaceuticals Launches Resolvin E1 Cancer Program and Scientific Advisory Board Read More
Dean A. Wetherbee 1/20/21 Dean A. Wetherbee 1/20/21 Thetis Pharmaceuticals Completes Pre-IND Meeting with FDA for its first-in-class Resolvin E1 Candidate Read More
Dean A. Wetherbee 12/14/20 Dean A. Wetherbee 12/14/20 Thetis Pharmaceuticals Receives Orphan Drug Designation for Resolvin E1 Program in Pediatric Ulcerative Colitis Read More
